Abstract
Accurate quantification of arterial blood T2 can be useful for non-invasive assessment of blood oxygenation and blood-brain barrier (BBB) function. While arterial spin labeling (ASL) combined with multi-echo readouts offers a contrast-agent-free approach to map arterial blood T2, in vivo applications remain challenging due to rapid signal decay and low signal-to-noise ratio (SNR) at longer echo times (TEs), likely leading to overestimation of T2 values. We propose a novel temporal evolution acquisition based ASL (TEA-ASL) sequence incorporating an optimized variable refocusing flip angle (RFA) train to preserve signal across all TEs. Data were acquired on a 5T MRI system combining a pseudo-continuous ASL (pCASL) with the proposed TEA readout with 12 echo times (32-384 ms). The variable RFA scheme significantly improved signal stability across the echo train compared to conventional acquisition with constant RFAs. Accuracy and clinical feasibility of the proposed method was validated by simulations, phantom scans, in-vivo test/retest experiments and in a patient with middle cerebral artery stenosis. The proposed TEA-ASL technique provides robust arterial T2 mapping at ultra-high field, offering a promising tool for probing oxygenation-related hemodynamics and BBB-associated pathophysiology.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Our institute receives funding from United Imaging Healthcare Co., Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University (IRB number: RJ2025300). Informed consent was obtained from all participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data and code used in this paper can be shared upon request to the corresponding author.
